

Viral Hepatitis Scorecard 2021

African Region

Hepatitis Scorecard

Member state	Country Burden						Country Response					
	Population (000 000)	Ag HBS Prevalence in general population (%)	Estimated number of chronic carriers in general population (000)	Ag HBS Prevalence among children under 5 (%)	Estimated number of chronic carriers among children under 5 (000)	Anti-HCV prevalence %	National Hepatitis Treatment Programme	National Strategic Plan for Viral Hepatitis	Testing and Treatment Guidelines	World Hepatitis Day 2021	HBV Birth Dose implemented	Hep B3 National coverage
Algeria	43	2.30	997	0.1	3.9	0.5	Y	Y	Y	N	Y	90
Angola	31.8	10.2	3351	4.6	264.6	0.6	Y	N	N	N	Y	80
Benin	11.8	9.3	1122	2.9	54.7	1.3	Y	Y	Y	Y	Y	82
Botswana	2.3	0.8	18.8	0.2	0.5	0.5	N	N	N	Y	Y	93
Burkina Faso	20.3	6.6	1379	1.7	57.6	1.4	Y	Y	Y	N	Y	91
Burundi	11.5	5.6	660.3	1.4	27.8	0.7	Y	Y	Y	Y	N	93
Cabo Verde	0.5	6.9	38	0.3	0.1	1.3	N	N	N	N	Y	98
Cameroon	25.9	6.6	1758	1.8	72	0.7	Y	Y	Y	Y	N	79
Central African Republic	4.7	7.6	366	3.8	27.7	0.6	Y	N	N	Y	N	60
Chad	16	19	3177	11	316	1.3	Y	N	N	Y	N	81
Comoros	0.9	5	43.9	1.2	1.4	0.7	N	N	N	Y	N	90
Congo	5.4	9	495	2.6	21	0.6	N	N	N	N	N	83
Côte d'Ivoire	25.7	10.7	2820	3.4	142	1.3	Y	N	N	Y	Y	93
Democratic Republic of the Congo	86.8	10.8	9652	3.3	518	0.6	Y	Y	N	N	N	95
Equatorial Guinea	1.4	8.7	122	6	12	0.6	Y	Y	N	N	Y	61
Eritrea	3.5	4.4	156	1	5	0.7	N	N	N	N	N	95
Eswatini	1	3.4	39	0.8	1.2	0.5	N	N	N	N	N	90
Ethiopia	112	4.9	5644	1.6	267	0.6	Y	Y	Y	Y	N	97
Gabon	2.2	7	160	2	6.8	0.6	N	N	N	N	N	70
Gambia	2.4	5.4	131	1.6	6.6	1.3	N	Y	N	N	Y	93
Ghana	30	9	2788	2	88.8	1.3	Y	N	Y	Y	N	98
Guinea	12.8	11.7	1542	6	127	1.3	Y	Y	Y	N	N	82
Guinea-Bissau	1.9	8.7	172	2	6.4	1.3	N	N	N	N	N	78
Kenya	53	1.7	893	0.4	28	0.7	N	Y	N	N	N	87
Lesotho	2	5.8	123	1.2	3	0.5	N	N	N	N	N	95
Liberia	5	13.5	684	4.7	34.5	1.3	N	N	N	N	N	87
Madagascar	27	6	1776	2	87.5	0.7	N	N	N	Y	N	95
Malawi	18.6	5	983	1.4	41	0.7	Y	N	N	N	N	96
Mali	19.7	10.8	2188	4.6	166	1.3	Y	Y	Y	Y	N	71
Mauritania	4.5	11	513	3.4	23	1.3	Y	Y	N	N	Y	90
Mauritius	1.3	2	26	0.4	0.3	0.7	N	N	N	N	N	98
Mozambique	30	2	613	0.6	30	0.7	Y	Y	Y	Y	N	95
Namibia	2.5	5.6	141	0.4	1.2	0.5	N	N	N	N	Y	88
Niger	23	10.9	2629	3.4	165	1.3	Y	Y	Y	Y	N	82
Nigeria	201	5.7	11679	3	998	1.3	Y	Y	Y	Y	Y	58
Rwanda	12.6	2.3	304	0.5	9.3	0.6	Y	Y	Y	N	N	98
Sao Tome and Principe	0.2	5.8	12.8	1.3	0.4	1.3	N	N	N	N	Y	95
Senegal	16	7.4	1230	0.9	24.4	1.3	Y	Y	Y	N	Y	100
Seychelles	0.1	0.5		0.1		0.7	N	N	N	N	N	100
Sierra Leone	7.8	8	635	2	23	1.3	N	N	N	N	N	95
South Africa	58.6	9	5374	3	178	0.5	N	N	N	N	N	85
South Sudan	11	18	2025	13	223	0.7	Y	Y	Y	N	N	50
Togo	8	13	1084	3	40	1.3	Y	N	N	N	N	90
Uganda	7	3.4	1574	1	74.5	0.6	Y	N	N	Y	N	73
United Republic of Tanzania	58	4	2538	1	97	0.2	Y	Y	Y	Y	N	98
Zambia	17.9	5	943	1.3	39	0.7	Y	Y	Y	Y	N	88
Zimbabwe	2.3	9.8	1463	2.7	57.4	0.5	N	N	N	N	N	90

Legend

Red: High endemicity >=8%
Yellow: No high endemicity

Red: prev >= 1%
Yellow: prev < =1%

Red: prev >= 1%
White: prev < 1%

Green: Yes
Red: No

Green: Yes
Red: No

Green: Yes
Red: No

Green: Yes
Red: No

Green: Yes
Red: No

Green: Hep B3 >=90%
Red: Hep B3 < 90%

Hepatitis Scorecard:

Explanatory notes

What Story are the indicators trying to tell us?

Population	General Population in the country, per million Source: United Nations, Population Division. The World Population Prospects - the 2017 revision ". New York, 2017
HBV in Adults	Prevalence of hepatitis B in the general population and estimated number of people with chronic infection infection (ref: http://whohbsagdashboard.com/#hbv-country-profiles)
HBV in children <5 years	Prevalence of hepatitis B in the population < 5 years of age and estimated number of people with infection (ref: http://whohbsagdashboard.com/#hbv-country-profiles)
HCV prevalence	Prevalence of hepatitis C infection among the general population at start of 2019 Source: Center for Disease Analysis estimates
National Hepatitis Treatment Programme	Existence of a Hepatitis Program in the country, can be integrated or stand alone, with a staff handling hepatitis activities. Important for clinical evaluation and treatment of viral hepatitis B and C and requires public health approach and decentralization
National Strategic plan	National strategic plans for viral hepatitis. Countries with high burden of disease require disease specific plans developed at the most focused with time bound interventions.
Testing and Treatment Guidelines	Existence of testing and treatment guidelines adapted from the WHO recommendations on testing and treatment of Hepatitis
MoH World Hepatitis Day	Leadership of MoH in the commemoration of World Hepatitis day 2021. Important for advocacy and Government action.
HBV Birth dose implemented	Monovalent hepatitis B birthdose within 24 hours is required for hepatitis B –PMTCT. 25 countries were expected to uptake the Birth Dose Vaccination in 2020. And now, 35 are expected for 2025
National coverage of 3rd dose pentavalent vaccination (10)	Shows the coverage of the Pentavalent vaccination which contains DPT, HiB and hepatitis B. 2020 target of >90% (GHSS). In green, countries with Hep B3 coverage >= 90% (ref: http://whohbsagdashboard.com/#hbv-country-profiles)